Smoking Cessation: What Actually Helps People Quit

Quitting smoking is the single highest-yield change most people who smoke can make for their long-term health. The body begins to recover within minutes of the last cigarette and continues along a documented timeline that runs out for decades. The approach with the strongest evidence base combines behavioral support (counseling, a quitline, a group, or an app) with one of several FDA-approved medications, used together rather than either on its own. The US Preventive Services Task Force gives this combination a Grade A recommendation for adults.

One part of the picture is genuinely contested. The most recent Cochrane review on nicotine e-cigarettes for cessation found high-certainty evidence they help more than nicotine replacement therapy, while the World Health Organization and the USPSTF do not endorse e-cigarettes as a cessation tool at the population level. This guide presents both findings in the same section, without endorsing vaping and without dismissing the trial evidence. It is general, educational, and not a treatment plan for any individual.

The essentials at a glance

• Quitting at any age is beneficial. According to CDC, heart rate drops within minutes, blood nicotine reaches zero by 24 hours, carbon monoxide drops to a non-smoker's level within several days, and longer-term risks of heart disease, stroke, and several cancers decline over years (compared with someone who keeps smoking).
• The most effective approach combines behavioral support (counseling, quitline, group, app) with FDA-approved pharmacotherapy. This is the central finding of the 2008 US Public Health Service Clinical Practice Guideline and carries a Grade A recommendation from USPSTF (2021).
• Among single medications, nicotine replacement therapy reliably increases the chance of quitting (Cochrane 2018: RR about 1.55 vs control, across 133 trials and 64,640 participants). Varenicline and cytisine appear most effective among monotherapies in network meta-analysis (Cochrane 2023).
• On e-cigarettes the evidence is split. Cochrane 2024 found high-certainty evidence that nicotine e-cigarettes help more than nicotine replacement therapy for cessation (RR about 1.59). WHO (December 2023) and USPSTF (2021) do not endorse e-cigarettes as a cessation tool at the population level. They are not advised for people who do not already smoke, especially youth.
• Relapse during a quit attempt is normal, not failure. The 2008 PHS guideline treats tobacco dependence as a chronic relapsing condition; most people who eventually quit make several attempts before it sticks.

Why quitting is worth it: the recovery timeline

The CDC publishes a tabular cessation timeline on its Benefits of Quitting Smoking page, with the explicit note that risks described as dropping or decreasing refer to the benefits of cessation compared to continued smoking. Within minutes of the last cigarette, heart rate drops. By 24 hours, the level of nicotine in the blood drops to zero. Within several days, the carbon monoxide level in the blood drops to the level of someone who does not smoke. Across 1 to 12 months, coughing and shortness of breath decrease.

The medium-term timeline runs from 1 to 2 years (the risk of heart attack drops sharply), to 3 to 6 years (the added risk of coronary heart disease drops by half), to 5 to 10 years (the added risk of cancers of the mouth, throat, and voice box drops by half, and the risk of stroke decreases). By 10 years, the added risk of lung cancer drops by half after 10 to 15 years, and the risk of cancers of the bladder, esophagus, and kidney decreases.

The long-term timeline keeps going. By 15 years, the risk of coronary heart disease drops to close to that of someone who does not smoke. By 20 years, the risk of cancers of the mouth, throat, and voice box drops to close to that of someone who does not smoke, the risk of pancreatic cancer drops to close to that of someone who does not smoke, and the added risk of cervical cancer drops by about half. The underlying authoritative compendia are the 2014 US Surgeon General report "The Health Consequences of Smoking: 50 Years of Progress" and the 2020 US Surgeon General report "Smoking Cessation," which reconfirms that smoking cessation is beneficial at any age and that behavioral counseling plus FDA-approved cessation medications increase the chance of quitting.

What actually works: behavioral support and medication

The 2008 US Public Health Service Clinical Practice Guideline, "Treating Tobacco Use and Dependence," is the most-cited evidence base for what works. The guideline reviewed approximately 8,700 articles across more than 35 meta-analyses, with an independent 24-member expert panel commissioned by the Agency for Healthcare Research and Quality. Its central operational finding is that the combination of counseling or behavioral support and pharmacotherapy is more effective than either alone, and that even brief, repeated clinician advice is independently effective. The US Preventive Services Task Force translated this evidence base into a Grade A recommendation in 2021: clinicians should ask all adults about tobacco use, advise those who smoke to stop, and provide both behavioral interventions and FDA-approved pharmacotherapy.

Behavioral support in this context is a broad category. It includes counseling in person or by phone (state and national quitlines are a free, evidence-based example), group sessions, text-message and app-based programs, and brief structured advice from a clinician or pharmacist. The pattern that performs best in the literature is straightforward in shape: pick a quit date, line up behavioral support, line up an FDA-approved medication, and use both together rather than relying on one or the other on its own.

Medication options at a glance

What follows is a class-level overview, not a prescription. Choosing a specific medication and dose is a conversation for a clinician or pharmacist, who can take medical history, current medications, and personal preference into account.

Nicotine replacement therapy (NRT) is the most-studied class. The 2018 Cochrane review of NRT versus control pooled 133 trials and 64,640 participants and found a risk ratio of abstinence of about 1.55 (95% CI 1.49 to 1.61) for any form of NRT compared with control, with each of the six NRT forms (patch, gum, lozenge, inhaler, nasal spray, and oral spray, depending on the country) significantly increasing the chance of quitting. Combination NRT, typically a long-acting patch plus a short-acting form such as gum or lozenge used as needed for breakthrough cravings, is a common evidence-based pattern. Which form (or combination) fits best is a clinician or pharmacist conversation.

Varenicline (sold as Champix or Chantix) is one of the most effective monotherapies in the Cochrane 2023 component network meta-analysis covering hundreds of trials and roughly 150,000 participants. Varenicline alone and varenicline combinations were superior to bupropion, NRT, counseling, and placebo in that analysis. Whether varenicline is the right fit is a clinician conversation.

Bupropion (sold as Zyban or Wellbutrin SR) is also FDA-approved for smoking cessation. It is a non-nicotine medication originally developed as an antidepressant and now used at a specific dose schedule for cessation that a clinician or pharmacist will set.

Cytisine is a plant-derived medication that acts on nicotine receptors and is available in some countries (in parts of Europe and in Canada, for example) but is not FDA-approved in the US. The Cochrane 2023 network meta-analysis places cytisine among the most effective monotherapies. Availability and the right way to use it are a clinician or pharmacist conversation in the relevant country.

Across all of these medications, the consistent recommendation in the guidelines is to combine the medication with behavioral support rather than to use it on its own, and to talk to a clinician or pharmacist about which option is the right fit.

The e-cigarette question

This is the most genuinely contested area in the cessation literature, and it is worth presenting both findings honestly. The 2024 Cochrane review of electronic cigarettes for smoking cessation (Lindson and colleagues, CD010216.pub8) found high-certainty evidence that nicotine e-cigarettes increase quit rates compared with nicotine replacement therapy, with a risk ratio of about 1.59 (95% CI 1.29 to 1.93). In plain language, if about six in 100 quit with NRT, around eight to twelve quit with nicotine e-cigarettes over the same period. The review did not find evidence of substantial harms from nicotine-containing e-cigarettes when used for cessation, within the follow-up windows of the included trials.

The World Health Organization, in a 14 December 2023 statement, took a different framing. WHO stated plainly that "e-cigarettes as consumer products are not shown to be effective for quitting tobacco use at the population level," called for urgent action to prevent youth uptake, and flagged evidence of adverse population-level effects and aggressive marketing to young people. The US Preventive Services Task Force rates the evidence on e-cigarettes as a cessation tool in any adult as Grade I (insufficient evidence) and suggests clinicians direct patients to interventions with proven effectiveness and established safety.

The honest summary is that the individual-cessation evidence (favorable, high-certainty in trials) and the population-health framing (cautionary, focused on youth uptake and unknown long-term effects) are pointing in different directions, and both signals are real. For someone already smoking, e-cigarettes are one option among several to discuss with a clinician. The trial evidence does not establish long-term safety beyond the follow-up windows of the included studies, e-cigarettes are not harmless, and they are not advised for people who do not already smoke, especially young people. This guide takes no personal position on whether to vape; it reports what the evidence and the public-health bodies say, side by side.

Behavioral support and quitlines

Quitlines are free, evidence-based behavioral support, and they exist in many countries. In the United States, calling 1-800-QUIT-NOW connects callers to their state quitline; coverage includes every US state plus the District of Columbia, Guam, and Puerto Rico. A nationwide Spanish line, 1-855-DEJELO-YA, is also available, along with in-US nationwide language lines for Korean (1-800-556-5564), Vietnamese (1-800-778-8440), and Mandarin or Cantonese (1-800-838-8917).

In the United Kingdom, NHS stop smoking services are organized by home nation. In England, the free Smokefree National Helpline number is 0300 123 1044. In Scotland, Quit Your Way Scotland can be reached on 0800 84 84 84. In Wales, Help Me Quit can be reached on 0800 085 2219. In Northern Ireland, local stop smoking providers are listed on the Stop Smoking NI website. The England helpline number is for England only; readers in Scotland, Wales, or Northern Ireland should use the service for their home nation.

Elsewhere, the most reliable way to find a local equivalent is to search for "quit smoking helpline" together with a country name; many countries operate national or regional quitlines that this guide does not attempt to list exhaustively. Text-message programs, app-based coaching, and online courses are additional behavioral-support channels and pair well with medication.

The first 24 hours, the first week, the first month

A practical pattern that fits the evidence has a few moving parts. Setting a specific quit date one to two weeks out gives time to prepare. Telling the people around the quit attempt (household, close friends, sometimes a manager) reduces the friction of asking for a smoke-free environment. Removing cues from the home and car (lighters, ashtrays, leftover packs) lowers the rate of automatic reach-for-a-cigarette moments. Planning a few replacement behaviors for the specific situations that usually trigger a smoke (after meals, with coffee, on a work break, during a phone call) gives the brain a different default. Any medication should be started on the schedule the clinician or pharmacist recommended, since some medications are designed to begin before the quit date itself.

The first three days are usually the hardest physically, as nicotine withdrawal symptoms (irritability, difficulty concentrating, increased appetite, restlessness, sleep disruption) tend to peak in this window. Strong psychological cravings tend to peak across the first one to two weeks and then ease across the next one to three months, although shorter situational cravings can come and go for longer. Sleep, hydration, and light movement help in the early days. A useful coffee-strength heads-up: caffeine metabolism slows when smoking stops, so the same cup of coffee can feel noticeably stronger than before. That is the caffeine landing harder, not a withdrawal symptom; dropping back by half a cup is often enough to even it out.

Special populations: a one-line signpost each

Pregnancy: USPSTF (2021) gives behavioral interventions a Grade A recommendation in pregnancy and rates pharmacotherapy in pregnancy as Grade I (insufficient evidence); the right way through is a conversation with an obstetric clinician or midwife who knows the individual situation.

Cardiovascular disease: quitting is one of the highest-yield interventions for cardiovascular risk; the choice of pharmacotherapy after a cardiac event is a clinician conversation.

Mental-health populations: cessation is achievable, the long-term mental-health outcome of quitting tends to be favorable, and the combination behavioral plus pharmacotherapy gold standard still applies; coordinating with the existing mental-health care team makes the pieces fit.

Frequently asked questions

How long does it take for my body to recover after I quit smoking?

Per CDC, heart rate drops within minutes of the last cigarette; the level of nicotine in the blood drops to zero by 24 hours; carbon monoxide in the blood drops to the level of someone who does not smoke within several days; coughing and shortness of breath decrease across 1 to 12 months; the risk of heart attack drops sharply at 1 to 2 years; the added risk of coronary heart disease drops by half at 3 to 6 years; and by about 15 years the risk of coronary heart disease drops close to that of someone who does not smoke. CDC notes that these reductions are described relative to continued smoking.

What is the most effective way to quit smoking?

The most-effective approach in the evidence base is combining behavioral support (counseling, quitline, group, or app) with FDA-approved pharmacotherapy. The US Preventive Services Task Force gives this combination a Grade A recommendation for adults (USPSTF 2021), based on the US Public Health Service Clinical Practice Guideline (2008 update). Which specific medication is the right fit is a conversation for a clinician or pharmacist.

Are e-cigarettes a good way to quit smoking?

The evidence is split. The 2024 Cochrane review found high-certainty evidence that nicotine e-cigarettes increase quit rates compared with nicotine replacement therapy (RR about 1.59) and did not find evidence of substantial harms within trial follow-up windows. The World Health Organization (December 2023) and the US Preventive Services Task Force (2021, Grade I) do not endorse e-cigarettes as a cessation tool at the population level. For someone already smoking, e-cigarettes are one option to discuss with a clinician; long-term safety beyond trial follow-up is not yet established, and they are not advised for people who do not already smoke, especially young people.

How long do nicotine cravings last after I quit?

Physical withdrawal symptoms usually peak in the first three days and ease across the next one to two weeks. Strong psychological cravings tend to peak across the first one to two weeks and continue to fade across the next one to three months, although shorter situational cravings can come and go for longer.

What if I relapse? Have I failed?

The 2008 US Public Health Service Clinical Practice Guideline treats tobacco dependence as a chronic relapsing condition, and most people who eventually quit make several attempts before it sticks. A relapse is information about what was missing, not evidence that the next attempt will fail. Restarting medication and behavioral support promptly tends to work better than waiting for a fresh start.

Is it safe to use NRT or other quit-smoking medications while I am pregnant?

The US Preventive Services Task Force (2021) gives behavioral interventions a Grade A recommendation in pregnancy and rates the evidence on pharmacotherapy in pregnancy as insufficient (Grade I). This is a conversation for an obstetric clinician or midwife who knows the individual situation.

References

1. 1Benefits of Quitting Smoking (page last reviewed 15 May 2024) · Centers for Disease Control and Prevention. Accessed 2026-05-28.
2. 2The Health Consequences of Smoking: 50 Years of Progress. A Report of the Surgeon General (2014) · US Department of Health and Human Services / Centers for Disease Control and Prevention (NCBI Bookshelf NBK179276). Accessed 2026-05-28.
3. 3Smoking Cessation: A Report of the Surgeon General (2020) · US Department of Health and Human Services / Centers for Disease Control and Prevention (NCBI Bookshelf NBK555591). Accessed 2026-05-28.
4. 4Treating Tobacco Use and Dependence: 2008 Update. Clinical Practice Guideline (Fiore MC, Jaen CR, Baker TB, et al.) · US Department of Health and Human Services, Public Health Service / Agency for Healthcare Research and Quality (NCBI Bookshelf NBK63952). Accessed 2026-05-28.
5. 5Nicotine replacement therapy versus control for smoking cessation (Hartmann-Boyce J, Chepkin SC, Ye W, Bullen C, Lancaster T), Cochrane Database of Systematic Reviews 2018, Issue 5, CD000146.pub5 · Cochrane Library. Accessed 2026-05-28.
6. 6Pharmacological and electronic cigarette interventions for smoking cessation in adults: component network meta-analyses (Lindson N, Theodoulou A, Ordonez-Mena JM, et al.), Cochrane Database of Systematic Reviews 2023, Issue 9, CD015226.pub2 · Cochrane Library. Accessed 2026-05-28.
7. 7Electronic cigarettes for smoking cessation (Lindson N, Butler AR, McRobbie H, Bullen C, Hajek P, Begh R, Theodoulou A, Notley C, Rigotti NA, Turner T, Livingstone-Banks J, Morris T, Hartmann-Boyce J), Cochrane Database of Systematic Reviews 2024, Issue 1, CD010216.pub8 · Cochrane Library (PubMed PMID 38189560). Accessed 2026-05-28.
8. 8Urgent action needed to protect children and prevent the uptake of e-cigarettes (14 December 2023) · World Health Organization. Accessed 2026-05-28.
9. 9Tobacco Smoking Cessation in Adults, Including Pregnant Persons: Interventions (final recommendation, 19 January 2021) · US Preventive Services Task Force. Accessed 2026-05-28.
10. 10How to Quit Smoking (and Quitlines and Other Cessation Support Resources) · Centers for Disease Control and Prevention. Accessed 2026-05-28.
11. 11NHS stop smoking services help you quit (Smokefree National Helpline 0300 123 1044 for England; Quit Your Way Scotland 0800 84 84 84; Help Me Quit Wales 0800 085 2219; Stop Smoking NI) · National Health Service (UK). Accessed 2026-05-28.
12. 12Better Health: Quit smoking · National Health Service (UK). Accessed 2026-05-28.